Associated Papers
Pathogenic variation in human DNA damage repair genes was originated from the evolutionary process of modern humans.
Li J et al.
Genes & Diseases, 2026
Innovative Drug and Prodrug Candidates in Cancer Treatment Targeting TP53 Mutations: Challenge and Hope.
Al-Zoubi RM et al.
Drug Development Research, 2026
Evaluation of non-canonical p53 functions in DNA replication and recombination for variant classification.
Jansche R et al.
Cell Death & Disease, 2026
CRISPR-based functional genomics for dissecting therapeutic dependency in primary acute myeloid leukemia samples.
Cao Z et al.
Molecular Cell, 2026
LINE-1 retrotransposition is a recurrent cause of MET exon 14 skipping in cancer.
Karlow JA et al.
Biorxiv : the Preprint Server for Biology, 2026
Molecular and histopathological insights into renal neuroendocrine tumors (RenNETs): A comprehensive study.
Zhang K et al.
Pathology, Research and Practice, 2026
Lung cancer-enriched p53 mutants occupy canonical p53 target genes without activating transcription, revealing a distinct loss-of-function behavior.
Tracewell MA et al.
Biorxiv : the Preprint Server for Biology, 2026
Circulating cell-free DNA profiling reveals ancestry-dependent genetic variation in metastatic prostate cancer.
Maleknia S et al.
Molecular Biomedicine, 2026
Utility of Next-Generation Sequencing in Renal Neoplasia, Including Tumors With Clear Cytoplasm and Rare Phenotypes (ELOC/MITF Alterations and Mismatch Repair Deficiency).
McCarthy M et al.
Mayo Clinic Proceedings, 2026
Genomic Insights into Cutaneous Squamous Cell Carcinoma.
Saglimbeni GS et al.
Cancers, 2026
Variant reclassification in cancer susceptibility genes and an updated variant spectrum of Turkish breast and colorectal cancer patients.
Can ND et al.
Human Genomics, 2026
Precision oncology in Bulgaria: a prospective study of metastatic colorectal cancer patients.
Dimitrov G et al.
Cancer Treatment and Research Communications, 2026
Attenuated Li-Fraumeni syndrome with TP53 p.R181H in a Japanese patient with metastatic rectal adenocarcinoma: a case report.
Kasahara Y et al.
Familial Cancer, 2026
Single-cell profiling reveals reprogrammed hierarchy and disrupted immune-stromal ecosystem in TP53-mutated AML.
Qiu G et al.
Experimental Hematology & Oncology, 2026
Beyond somatic mutations: the role of next-generation sequencing in identifying germline predisposition in patients with acute myeloid leukemia.
Loghavi S et al.
Haematologica, 2026
Correlation between P53 immunohistochemical staining and TP53 molecular testing in endometrial carcinomas: a detailed assessment of discrepant cases with implications for patient management.
Machuca-Aguado J et al.
Histopathology, 2026
Mutant p53 Regulates Pyruvate Dehydrogenase Kinase 1 (PDK1) to Promote Proliferation and Migration in Breast Cancer.
Ye Y et al.
Cancer Science, 2026
Using the Reactome Graph Database to generate pathway fingerprints for cancer-related genes, and using the fingerprints to gain insights into cancer, comorbidity, and cancer gene networks.
Iengar P et al.
Computational Biology and Chemistry, 2026
Thyroblastoma as a manifestation of DICER1 syndrome with confirmed germline mutation and comprehensive literature review.
Yin L et al.
Virchows Archiv : an International Journal of Pathology, 2026
Etiology of TP53 mutated complex karyotype acute myeloid leukemia.
Fedenko A et al.
Leukemia, 2026
Next-Generation Sequencing-Based Detection of KRAS G12D Variants in Colorectal Cancer: A Retrospective Cohort Study.
Hekimoglu G et al.
Genes, 2026
TP53 mutation predict poor prognosis in diffuse large B-cell lymphoma: a single-center study.
Zhang H et al.
Annals of Hematology, 2026
Common gene mutations in 103 authenticated colorectal cancer cell lines.
Kranjec C et al.
Oncogenesis, 2026
Correlation analysis of TP53 missense mutations and p53 protein expression patterns in endometrial carcinoma.
Yang Y et al.
Human Pathology, 2026
TP53 mutation heterogeneity reveals distinct prognoses in mantle cell lymphoma.
Liu S et al.
Annals of Hematology, 2026
ΔNp73 isoform defines a TP53-mutant-like poor-risk subgroup of acute myeloid leukemia.
Pereira-Martins DA et al.
Cell Reports. Medicine, 2026
Dual Targeting of Mutant p53 and SNRPD2 via Engineered Exosomes Modulates Alternative Splicing to Suppress Ovarian Cancer.
Zhao W et al.
Advanced Science (weinheim, Baden-wurttemberg, Germany), 2026
T cell receptor-engineered T cells targeting the TP53R248Q neoantigen elicit antitumor effects in human cancer models.
Shen L et al.
The Journal of Clinical Investigation, 2026
Restoration of the Y220C p53 Full-Length Mutant by PK11000: a Molecular Dynamics Study of an Intrinsically Disordered Protein.
Stetson S et al.
Acs Omega, 2026